News for Zelira Therapeutics Limited (ZLDAF)

Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a leading player in cannabinoid medicine research, has successfully demonstrated that its proprietary drug for diabetic nerve pain, ZLT-L-007, surpasses the efficacy of Pfizer Inc. (NYSE:

Research finds finds most Australians are still medicating with illicit cannabis, although numbers accessing legal prescription have risen.

The first of new products is set to be delivered by the end of FY23.

March 22, 2023 (Investorideas.com Newswire) KEY INSIGHTS & TAKEAWAYS CAPITAL RAISES Four capital raise transactions with total disclosed proceeds of $4.4M clo...

The ASX health sector is down more than 8% as 2022 comes to end but in signs of optimism for 2023, Morgans has a basket of stocks to watch.

The competition to become the world’s supplier of medicinal cannabis is hotting up. Australian weed companies are getting into the action.

Creso Pharma (ASX:CPH) has taken the final step in its acquisition of Health House International (ASX:HHI).

Missouri and Maryland have just voted to legalise weed and Arkansas, North Dakota and South Dakota could be next.

Less than 30 years after Israel became the first nation in the world to allow its citizens to use cannabis for medical purposes, the medical and adult-use cannabis markets have spread across the globe at a dizzying rate.

Read the ultimate guide on ASX cannabis stocks, companies and pricing. Gain advice to uncover market conditions and investing opportunities.

Researchers say data shows transition from illicit to legal use of cannabis, with medicinal users up 34.5% since 2018.

Uranium gets closer to officially green, history says Buy The Dip, and picking bottoms with Opal Capital.

Aussie small caps have copped a commodities shellacking as materials, metals and energy stocks bear the brunt of the economic angst

Investors are factoring in inflationary price increases - with no effect on market indices. In fact, share prices keep grinding higher.